AVBPArriVent BioPharma, Inc.

$16.72-5.3% 1Y

$16.72

$15.1252 weeks$33.83

AVBP in its own filings

Nothing in AVBP's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.

Events found in the filings · across 154 filings · the record starts in 2023

Hard flags: none
Hard flags
Most recent filing: Oct 6, 2026
Most recent filing · Form 8-K
Record starts: Sep 27, 2023
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Nov 9, 2026
Change in certifying accountantpast_3y: 2025-03-13
SEC comment-letter activity8 occurrences: 2024-01-23

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Oct 6, 2026The information set forth in the press release referred to in.Regulation FD disclosure · Form 8-K
Aug 12, 2026On August 11, 2026, ArriVent BioPharma, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Allist License Agreement”) with Shanghai Allist Pharmaceuticals Co., Ltd. (“Allist”), a pharmaceutical company incorporated under the laws of China.Material agreement entered · Form 8-K
May 11, 2026On May 11, 2026, ArriVent BioPharma, Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) a prospectus supplement (the “Prospectus Supplement”), dated May 11, 2026, with respect to the Company’s existing “at the market offering” program (the “ATM Program”)Other event · Form 8-K
Mar 17, 2026The information set forth in the press release referred to in.Regulation FD disclosure · Form 8-K
Sep 9, 2025The information set forth in the press release referred to in.Regulation FD disclosure · Form 8-K